PASADENA, Calif.--(BUSINESS WIRE)--Fuzionaire Diagnostics (“Fuzionaire Dx”), in partnership with Tokyo-based radiopharmaceutical company Japan Medical Isotope Technology Development K.K. (“JAMIT”), today announced the launch of Fuzionaire Radioisotope Technologies K.K. (“FRIT”). FRIT will work to commercialize Fuzionaire Dx’s technology in Japan, expanding Fuzionaire Dx’s fluorine-18 radiolabeling platform through partnerships with Japanese pharmaceutical companies and research institutions and exploring new possibilities in alpha-emitting radiotherapeutics for cancer treatment.
The company will be led by Hiroshi Nakashita, MD, experienced in pharmaceutical industry commercial operation. Dr. Nakashita also has deep functional experience in health care policy shaping in Ministry of Health, Labour and Welfare Japan as a government official earlier in his career. Dr. Nakashita will serve as FRIT’s CEO.
“Fuzionaire’s technologies open up new possibilities for disease diagnosis and treatment,” said Dr. Nakashita, CEO of FRIT. “After years of delay in research and development in these areas due to the political landscape, we are thrilled to have the technology and talent to bring necessary advancements to our country.”
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
Dr. Nakashita is joined by founding special advisor Takeo Morooka, MD, MPH, co-founder and CEO of JAMIT, and founder of the Japan Foundation of Medical Isotope Development (“JAFMID”), whose work is aimed at advancing medicine, promoting population health, and developing the medical industry in Japan by addressing technological, manufacturing, and regulatory issues in medical isotope development. Dr. Morooka successively held important positions in pharmaceutical and medical device industry.
“After the Fukushima disaster, new restrictions were implemented in Japan that have impacted nuclear medicine,” said Dr. Morooka, special advisor to FRIT. “We believe JAMIT’s and Fuzionaire Diagnostics’ joint efforts through Fuzionaire Radioisotope Technologies K.K. could accelerate the critical development of radiopharmaceuticals in Japan and add to the conversation about the importance of medical isotope technologies in Japan and the world.”
Based on a breakthrough in catalysis by Chief Science Officer Anton Toutov, PhD, Fuzionaire Dx’s chemistry platform dramatically accelerates radiopharmaceutical discovery and improves manufacturing of radiolabeled molecules. This fundamentally changes the way in which researchers and clinicians are able to detect and treat disease.